Showing 12,001 - 12,020 results of 42,192 for search '(( 50 ((ng decrease) OR (((we decrease) OR (a decrease)))) ) OR ( a point decrease ))', query time: 1.39s Refine Results
  1. 12001

    Assessment of Membrane Fluidity Fluctuations during Cellular Development Reveals Time and Cell Type Specificity - Fig 2 by Pakiza Noutsi (3160734)

    Published 2016
    “…At 72 h GP reached maximum values (0.45) ± SEM and decreased to 0.25 ± SEM after 92 h. 10 cells were analyzed for each time point for statistical significance. d) Histograms of GP distributions among L6 cells at 12 h, 48 h, 72 h and 92 h respectively. …”
  2. 12002

    Isoindolin-1-ones Fused to Barbiturates: From Design and Molecular Docking to Synthesis and Urease Inhibitory Evaluation by Houman Kazemzadeh (12742141)

    Published 2022
    “…In vitro urease inhibitory results indicated that all the compounds had higher inhibitory activity than the standard inhibitor, thiourea, and compound <b>5b</b> proved to be the most potent inhibitor (IC<sub>50</sub> = 0.82 ± 0.03 μM). A molecular docking study was performed to understand the interaction between compounds <b>5a–n</b> and Jack bean urease enzyme. …”
  3. 12003
  4. 12004

    Table_1_Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice.docx by Juan Liu (6492)

    Published 2021
    “…</p>Methods<p>We synthesized and purified rAlt a 1. Alternaria-sensitized and challenged mice received subcutaneous immunotherapy (SCIT) with four different rAlt a 1 dosages (5, 50, 100, and 150 µg) or PBS only. …”
  5. 12005

    Image_1_Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice.tif by Juan Liu (6492)

    Published 2021
    “…</p>Methods<p>We synthesized and purified rAlt a 1. Alternaria-sensitized and challenged mice received subcutaneous immunotherapy (SCIT) with four different rAlt a 1 dosages (5, 50, 100, and 150 µg) or PBS only. …”
  6. 12006

    Image_2_Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice.tif by Juan Liu (6492)

    Published 2021
    “…</p>Methods<p>We synthesized and purified rAlt a 1. Alternaria-sensitized and challenged mice received subcutaneous immunotherapy (SCIT) with four different rAlt a 1 dosages (5, 50, 100, and 150 µg) or PBS only. …”
  7. 12007

    GFP+ NPC Implant Apoptosis. Implants were sectioned and immunostained for the early effector caspase, cleaved caspase-3 (red, GFP = green, DAPI = blue) and area of fluorescence rel... by Cicely Williams (291856)

    Published 2013
    “…<p>This initially higher rate of apoptosis significantly decreased by day 5 (0.036±0.050, p = 0.0063) to a rate comparable to that of the NPC∶BEC implants. …”
  8. 12008

    Study on the Effects of Nonelectrolyte Additives on the Phase, Thermodynamics, and Structural Changes in Micelles of Silicone Surfactants in Aqueous Solutions from Surface Activity... by Saurabh S. Soni (1708960)

    Published 2003
    “…The influence of given additive on the micellization of silicone surfactants was monitored from the changes in the free energy of micellization values for the surfactant solutions in water and water + additives. The cloud points and the critical micelle concentration values for the surfactant solutions were found to be decreased in the presence of the selected three additives. …”
  9. 12009

    <i>In silico</i> screening identifies doxazosin as a novel agonist for EphA2 receptor. by Aaron Petty (143170)

    Published 2012
    “…Note decreasing amount of EphA2 following ephrin-A1 and doxazosin treatment. …”
  10. 12010
  11. 12011

    Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study by David N. Franz (822882)

    Published 2016
    “…Everolimus was initiated at a dose (4.5 mg/m<sup>2</sup>/day) titrated to a target blood trough of 5–15 ng/mL. …”
  12. 12012
  13. 12013
  14. 12014
  15. 12015
  16. 12016
  17. 12017

    DataSheet_2_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.docx by Joaquin Garcia-Solorio (18296686)

    Published 2024
    “…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
  18. 12018

    DataSheet_1_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.xlsx by Joaquin Garcia-Solorio (18296686)

    Published 2024
    “…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
  19. 12019

    Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients by Sivan Yannai (3594626)

    Published 2019
    “…<div><p>Familial Dysautonomia (FD) is an autosomal recessive congenital neuropathy that results from a point mutation at the 5’ splice site of intron 20 in the <i>IKBKAP</i> gene. …”
  20. 12020